C38 UNDERSTANDING THERAPEUTICS IN IPF: Effect Of Pirfenidone On All-Cause Mortality (acm) And Forced Vital Capacity (FVC) In Idiopathic Pulmonary Fibrosis (ipf) Patients With Low FVC And/or Low Dlco: Analysis Of Pooled Data From Ascend And Capacity

Rationale: The pivotal trials of the two approved therapies in IPF, pirfenidone and nintedanib, assessed patients with mild to moderate disease as defined per protocol in these studies. [...]the effect of pirfenidone in patients with more severe lung function impairment warrants further investigatio...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 195
Main Authors Nathan, S D, Costabel, U, Albera, C, Kirchgassler, K-U, Chou, W, Noble, P W
Format Journal Article
LanguageEnglish
Published New York American Thoracic Society 01.01.2017
Subjects
Health risk assessment
Pulmonary fibrosis
Online AccessGet full text

Cover

More Information
Summary:Rationale: The pivotal trials of the two approved therapies in IPF, pirfenidone and nintedanib, assessed patients with mild to moderate disease as defined per protocol in these studies. [...]the effect of pirfenidone in patients with more severe lung function impairment warrants further investigation. Here, we present pooled subgroup analyses from ASCEND and CAPACITY for patients with low baseline %FVC (< 50%) and/or low percent predicted diffusing capacity for carbon monoxide (%DLco < 35%) to further inform on treatment effect of pirfenidone in patients with more severe lung function impairment.
ISSN:1073-449X
1535-4970